Azam Hashemi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Azam Hashemi has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Yasaman Ghodsi Boushehri
Shiraz University of Medical Sciences, Shiraz, Iran
2 shared publicationsAkram Nourian
Rajaie Cardiovascular Medical and Research Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
1 shared publicationEhsan Zare Sangderazi
Medical doctor, Faculty of Medicine, Shahid Sadoughi University of Medical sciences, Yazd, Iran
1 shared publicationElnaz Sheikhpour
Hematology and Oncology Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
1 shared publicationFarimah Shamsi
Center of Healthcare Data Modeling, Department of Biostatistics and Epidemiology, School of Public Health, Shahid Sadoughi University of Medical sciences, Yazd, Iran
1 shared publicationFatemeh Pourrajab
Nutrition and Food Security Research Centre, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
1 shared publication
Latest Publications
- 3 January 2023
- Published by Knowledge E DMCC in Iranian Journal of Pediatric Hematology and Oncology
- Vol. 13 (1) , 7-12
Investigating the effect of sodium chloride on the prevention of mucormycosis fungal infection in children with acute lymphocytic leukemia during treatment
Background: Given that no comprehensive study was conducted regarding the effect of sodium chloride on the prevention of mucormycosis fungal infection in acute leukemia patients during treatment, this study aimed the investigating the effect of sodium chloride on the prevention of mucormycosis fungal infection in acute lymphocytic leukemia patients during treatment. Materials and Methods: This retrospective study was conducted on children with ALL who were undergoing chemotherapy in the induction phase and were susceptible to fungal and infectious diseases. Then 84 patients were randomly divided into the two groups. One group (n=46) received nasal drop containing sodium chloride (NORMONIX, 0.65%, three times a day) as the intervention group during treatment and another group did not receive sodium chloride (control group)(n=38). If the symptoms of mucormycosis was observed and detected (positive test), the injection of amphotrypsin B was started. Results: In the current study, 84 patients entered the study. The mean age of patients in the control group and the intervention group was 7.84±3.45, and 6.45±3.4 years, respectively (P>0.05). Positive mucormycosis was seen in 24 (63.2%) patients in the control group and 16 (34.78%) patients in the intervention group (P=0.01). Conclusion: According to the findings of this study, the frequency of patients with positive mucormycosis in the NaCl group was significantly lower than the control group. Therefore, it seems that NaCl drop can be effective regarding reducing the incidence of mucormycosis fungal infection and can decrease the need to amphotrypsin B, but further studies should be conducted in this regard.
- 3 January 2023
- Published by Knowledge E DMCC in Iranian Journal of Pediatric Hematology and Oncology
- Vol. 13 (1) , 7-12
Investigating the effect of sodium chloride on the prevention of mucormycosis fungal infection in children with acute lymphocytic leukemia during treatment
Background: Given that no comprehensive study was conducted regarding the effect of sodium chloride on the prevention of mucormycosis fungal infection in acute leukemia patients during treatment, this study aimed the investigating the effect of sodium chloride on the prevention of mucormycosis fungal infection in acute lymphocytic leukemia patients during treatment. Materials and Methods: This retrospective study was conducted on children with ALL who were undergoing chemotherapy in the induction phase and were susceptible to fungal and infectious diseases. Then 84 patients were randomly divided into the two groups. One group (n=46) received nasal drop containing sodium chloride (NORMONIX, 0.65%, three times a day) as the intervention group during treatment and another group did not receive sodium chloride (control group)(n=38). If the symptoms of mucormycosis was observed and detected (positive test), the injection of amphotrypsin B was started. Results: In the current study, 84 patients entered the study. The mean age of patients in the control group and the intervention group was 7.84±3.45, and 6.45±3.4 years, respectively (P>0.05). Positive mucormycosis was seen in 24 (63.2%) patients in the control group and 16 (34.78%) patients in the intervention group (P=0.01). Conclusion: According to the findings of this study, the frequency of patients with positive mucormycosis in the NaCl group was significantly lower than the control group. Therefore, it seems that NaCl drop can be effective regarding reducing the incidence of mucormycosis fungal infection and can decrease the need to amphotrypsin B, but further studies should be conducted in this regard.
- 3 January 2023
- Published by Knowledge E DMCC in Iranian Journal of Pediatric Hematology and Oncology
- Vol. 13 (1) , 1-6
The effect of echinacea in the prevention of upper respiratory infections in children with acute lymphoblastic leukemia
Background: The efficacy of echinacea products to treat upper respiratory tract infections (URTI) has been shown in some studies, however, there are few studies considering the efficacy of echinacea to prevent URTI. Therefore this study aimed to assess the effect of echinacea in the prevention of URTI in these children. Materiala and Methods: This retrospective cross-sectional study was conducted on 60 children with ALL in Shahid Sadoughi hospital from September 2020 to September 2021. These Children were divided into two groups (n=30). The case group received immunogen syrup, containing echinacea purpura root extract (200 mg/ml). This syrup was prescribed in the intervention group as 2 ml for children in the age range of 2-8 years and 0.5 ml for children in the age range of 1-2 years old for 3 months. The control group did not receive echinacea syrup. These patients were followed for 3 months regarding URTI. Results: The frequency of URTI in the case and control groups was 40% and 66.7%, respectively, and a significant difference was noted between the two groups in terms of the frequency of URTI (P<0.05). Moreover, 23.3% of patients who received echinacea developed a second URTI, while 53.3% of patients who did not receive echinacea developed a second URTI (P0.05). Conclusion: According to the results, echinacea can be effective in decreasing the occurrence of URTI in these children. Therefore, regarding the efficacy of echinacea in decreasing URTI, it is recommended to use echinacea in the prevention of URTI.
- 3 January 2023
- Published by Knowledge E DMCC in Iranian Journal of Pediatric Hematology and Oncology
- Vol. 13 (1) , 1-6
The effect of echinacea in the prevention of upper respiratory infections in children with acute lymphoblastic leukemia
Background: The efficacy of echinacea products to treat upper respiratory tract infections (URTI) has been shown in some studies, however, there are few studies considering the efficacy of echinacea to prevent URTI. Therefore this study aimed to assess the effect of echinacea in the prevention of URTI in these children. Materiala and Methods: This retrospective cross-sectional study was conducted on 60 children with ALL in Shahid Sadoughi hospital from September 2020 to September 2021. These Children were divided into two groups (n=30). The case group received immunogen syrup, containing echinacea purpura root extract (200 mg/ml). This syrup was prescribed in the intervention group as 2 ml for children in the age range of 2-8 years and 0.5 ml for children in the age range of 1-2 years old for 3 months. The control group did not receive echinacea syrup. These patients were followed for 3 months regarding URTI. Results: The frequency of URTI in the case and control groups was 40% and 66.7%, respectively, and a significant difference was noted between the two groups in terms of the frequency of URTI (P<0.05). Moreover, 23.3% of patients who received echinacea developed a second URTI, while 53.3% of patients who did not receive echinacea developed a second URTI (P0.05). Conclusion: According to the results, echinacea can be effective in decreasing the occurrence of URTI in these children. Therefore, regarding the efficacy of echinacea in decreasing URTI, it is recommended to use echinacea in the prevention of URTI.
- Open Access
- 1 May 2020
- Published by Taylor & Francis in Journal of Experimental Pharmacology
- Vol. ume 12, 107-128
Molecular Targeting and Rational Chemotherapy in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a molecularly complex disease with multiple aberrant genetic pathways involved in its pathogenesis. Approximately one-third to one-half of patients with AML would relapse, and no standard therapy is established for relapsing and/or refractory AML (RR-AML) yet. It is unlikely that blockage of only one specific pathway will lead to prolonged remissions and cures in all fractions of the AML patients population. Nowadays, novel therapeutic agents with rational combination are being recognized which improve the cure rate for relapsed AML. These drugs and their metabolites impart unique properties in the interaction with each of the intracellular targets and metabolic enzymes whereby resulting in unique clinical activity. To date, most of the combinations have used a targeted agent combined with standard agents such as anthracyclines, cytarabine, or hypomethylating agents to improve the outcome. Rational combinations of DNA damage-inducing therapies with DNA methyltransferase and histone deacetylase inhibitors synergistically enhance the DNA damage, growth inhibition and apoptosis of myeloid cells. This review makes a thorough look at current antineoplastic agents for AML with emphasis on its genetics and molecular mechanisms of action and the role of combination regimens.
- 1 May 2020
- Published by Taylor & Francis in Journal of Experimental Pharmacology
- Vol. ume 12, 107-128
Open AccessMolecular Targeting and Rational Chemotherapy in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a molecularly complex disease with multiple aberrant genetic pathways involved in its pathogenesis. Approximately one-third to one-half of patients with AML would relapse, and no standard therapy is established for relapsing and/or refractory AML (RR-AML) yet. It is unlikely that blockage of only one specific pathway will lead to prolonged remissions and cures in all fractions of the AML patients population. Nowadays, novel therapeutic agents with rational combination are being recognized which improve the cure rate for relapsed AML. These drugs and their metabolites impart unique properties in the interaction with each of the intracellular targets and metabolic enzymes whereby resulting in unique clinical activity. To date, most of the combinations have used a targeted agent combined with standard agents such as anthracyclines, cytarabine, or hypomethylating agents to improve the outcome. Rational combinations of DNA damage-inducing therapies with DNA methyltransferase and histone deacetylase inhibitors synergistically enhance the DNA damage, growth inhibition and apoptosis of myeloid cells. This review makes a thorough look at current antineoplastic agents for AML with emphasis on its genetics and molecular mechanisms of action and the role of combination regimens.
- Open Access
- 1 January 2014
- Vol. 4 (4) , 188-190
A Case Report: Acute Myeloid Leukemia (FAB M7)
Acute myeloid leukemia (AML-M7) is a type of pediatric AML accounting for 3-10% of primary childhood AML and children may present with a broad variety of symptoms including low-grade fever, diarrhea, easy bruising, failure to gain weight and life-threatening conditions. We report a rare case of AML. A 26-month-old boy who presented with weakness and fatigue. He was diagnosed as a case of AMLM-7 on the basis of peripheral blood finding, bone marrow examination report and immune phenotyping.
- 1 January 2014
- Vol. 4 (4) , 188-190
Open AccessA Case Report: Acute Myeloid Leukemia (FAB M7)
Acute myeloid leukemia (AML-M7) is a type of pediatric AML accounting for 3-10% of primary childhood AML and children may present with a broad variety of symptoms including low-grade fever, diarrhea, easy bruising, failure to gain weight and life-threatening conditions. We report a rare case of AML. A 26-month-old boy who presented with weakness and fatigue. He was diagnosed as a case of AMLM-7 on the basis of peripheral blood finding, bone marrow examination report and immune phenotyping.